To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD

Inclusion Criteria: * Age-related macular degeneration patients diagnosed with subfoveal choroidal neovascularization in the study eye, with all of the following characteristics required: * central subfield thickness \> 300 microns on investigator-determined OCT (inclusive of subretinal fluid) * active subfoveal leakage as determined by investigator-determined fluorescein angiography * minimally classic or occult with no classic CNV lesion * lesion size no greater than 12 disc areas * CNV \> 50% of lesion area * \< 50% of lesion area with blood * = 25% of lesion area with fibrosis * Best-corrected ETDRS visual acuity in the study eye between 80 to 24 letters inclusive (approximately 20/25 and 20/320 or 4/5 to 4/63) at screening * Female subjects must be of non-childbearing potential. Exclusion Criteria: * Additional eye disease in the study eye that could compromise best corrected visual acuity (i.e. glaucoma with documented visual field loss, clinically significant diabetic retinopathy, ischemic optic neuropathy, or retinitis pigmentosa). * CNV in the study eye due to other causes unrelated to age-related macular degeneration. * The presence of retinal angiomatous proliferation (RAP) in the study eye, as determined by the investigator (confirmation by indocyanine green angiography is not required). * Geographic atrophy involving the center of the fovea in the study eye. * Anterior segment and vitreous abnormalities in the study eye that would preclude adequ…